​

Contineum Therapeutics, Inc. Class A Ownership | Who Owns Contineum Therapeutics, Inc. Class A?

OverviewFinancialsChart

Contineum Therapeutics, Inc. Class A Ownership Summary

Contineum Therapeutics, Inc. Class A is owned by 58.44% institutional investors, 1.82% insiders, and 39.74% retail investors. Metlife investment management is the largest institutional shareholder, holding 0% of CTNM shares.

CTNM Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockContineum Therapeutics, Inc. Class A58.44%1.82%39.74%
SectorHealthcare Stocks 279.18%10.62%-189.80%
IndustryBiotech Stocks 63.96%10.74%25.30%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Metlife investment management---
Adage capital partners gp---
Polar capital---
Stempoint capital lp---
Winton group---

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Metlife investment management---
Adage capital partners gp---
Polar capital---
Stempoint capital lp---
Winton group---

Top Buyers

HolderShares% AssetsChange
Metlife investment management---7.03K
Winton group---39.74K
Polar capital---43.60K
Adage capital partners gp---200.00K
Stempoint capital lp---265.83K

Top Sellers

HolderShares% AssetsChange
Stempoint capital lp---265.83K
Adage capital partners gp---200.00K
Polar capital---43.60K
Winton group---39.74K
Metlife investment management---7.03K

Sold Out

HolderChange
Metlife investment management-7.03K
Winton group-39.74K
Polar capital-43.60K
Adage capital partners gp-200.00K
Stempoint capital lp-265.83K

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2025625.08%15,117,518-3.45%580.89%27-30.77%18100.00%
Dec 31, 20246017.65%15,782,18916.07%812.92%4066.67%9-40.00%
Sep 30, 2024514.08%13,597,5534.46%522.06%24-51.02%15-
Jun 30, 202449-13,016,510-50-49---

Recent Insider Transactions

DateNameRoleActivityValue
Nov 25, 2024Lorrain Daniel S. Chief Scientific OfficerSell$16.18K
Nov 18, 2024Lorrain Daniel S. Chief Scientific OfficerSell$99.73K
Nov 18, 2024Lorrain Daniel S. Chief Scientific OfficerSell$1.69K

Insider Transactions Trends

DateBuySell
2025 Q2--
2025 Q1--
2024 Q4-3
2024 Q2--

CTNM Ownership FAQ

Who Owns Contineum Therapeutics, Inc. Class A?

Contineum Therapeutics, Inc. Class A shareholders are primarily institutional investors at 58.44%, followed by 1.82% insiders and 39.74% retail investors. The average institutional ownership in Contineum Therapeutics, Inc. Class A's industry, Biotech Stocks , is 63.96%, which Contineum Therapeutics, Inc. Class A falls below.

Who owns the most shares of Contineum Therapeutics, Inc. Class A?

Contineum Therapeutics, Inc. Class A’s largest shareholders are Metlife investment management (0 shares, 0%), Adage capital partners gp (0 shares, 0%), and Polar capital (0 shares, 0%). Together, they hold 0% of Contineum Therapeutics, Inc. Class A’s total shares outstanding.

Does Blackrock own Contineum Therapeutics, Inc. Class A?

BlackRock is not among the top 10 institutional shareholders of Contineum Therapeutics, Inc. Class A.

Who is Contineum Therapeutics, Inc. Class A’s biggest shareholder by percentage of total assets invested?

Metlife investment management is Contineum Therapeutics, Inc. Class A’s biggest shareholder by percentage of total assets invested, with 0% of its assets in 0 Contineum Therapeutics, Inc. Class A shares, valued at 0$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools